Danske Bank A S grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 44.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,107,117 shares of the biopharmaceutical company's stock after acquiring an additional 340,439 shares during the quarter. Danske Bank A S owned about 0.19% of Royalty Pharma worth $64,611,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. William Blair Investment Management LLC purchased a new position in Royalty Pharma in the third quarter valued at approximately $950,000. Allworth Financial LP raised its holdings in Royalty Pharma by 5.1% during the third quarter. Allworth Financial LP now owns 7,837 shares of the biopharmaceutical company's stock worth $439,000 after purchasing an additional 381 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Royalty Pharma during the 3rd quarter worth approximately $233,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. purchased a new stake in shares of Royalty Pharma during the 3rd quarter worth approximately $63,000. Finally, Maryland State Retirement & Pension System lifted its position in shares of Royalty Pharma by 15.0% during the 3rd quarter. Maryland State Retirement & Pension System now owns 26,428 shares of the biopharmaceutical company's stock worth $1,542,000 after buying an additional 3,449 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.
Insider Buying and Selling at Royalty Pharma
In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the firm's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the transaction, the executive vice president directly owned 270,401 shares of the company's stock, valued at approximately $15,826,570.53. This trade represents a 27.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 208,252 shares of company stock valued at $12,324,407. 18.84% of the stock is owned by insiders.
Royalty Pharma Price Performance
Shares of NASDAQ RPRX opened at $69.31 on Monday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. Royalty Pharma PLC has a twelve month low of $37.31 and a twelve month high of $70.37. The stock has a 50 day moving average of $61.51 and a two-hundred day moving average of $54.53. The stock has a market cap of $39.76 billion, a P/E ratio of 57.76, a P/E/G ratio of 1.37 and a beta of 0.36.
Royalty Pharma Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma's dividend payout ratio is 78.33%.
Analysts Set New Price Targets
Several research analysts have recently issued reports on RPRX shares. TD Cowen upped their target price on shares of Royalty Pharma from $65.00 to $68.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Bank of America reiterated a "buy" rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Royalty Pharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 11th. The Goldman Sachs Group reissued a "buy" rating and issued a $66.00 price target on shares of Royalty Pharma in a research report on Thursday, August 6th. Finally, Citigroup boosted their price target on shares of Royalty Pharma from $70.00 to $78.00 and gave the company a "buy" rating in a research report on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $63.29.
View Our Latest Report on Royalty Pharma
Royalty Pharma Company Profile
(
Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Further Reading
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.